Analyte sensor

Patent metadata

Field	Value
Publication number	US-9986942-B2
Application number	US-50336706-A
Country	US
Kind code	B2
Filing date	Aug 10, 2006
Priority date	Jul 13, 2004
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

Biointerface membranes are provided which can be utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device incorporating such membranes are provided.

First claim

The invention claimed is:

1. An analyte sensing device for detecting an analyte in a host, comprising:
a transcutaneous continuous sensor configured to measure a clinically useful analyte concentration in a tissue of a host for a time period from one day to fifteen days post implantation, the sensor comprising:
a sensor configured to measure an analyte in a host;
a sensing membrane located over the sensor; and
a biointerface membrane disposed on the sensing membrane, wherein the biointerface membrane is configured to interface with biological fluid, wherein the biointerface membrane has a dry thickness from 0.2 microns to 5 microns, wherein the biointerface membrane comprises a material that has from 20 wt. % to about 80 wt. % water during sensor use,

wherein the sensor has a sensitivity of 1 pA/mg/dL to 100 pA/mg/dL during a sensor session.

2. The device of claim 1 , wherein the biointerface membrane comprises a bioactive agent, wherein the bioactive agent comprises a substance that releases into the tissue upon implantation into the host, wherein the bioactive agent suppresses wound healing by promoting irritation and/or inflammation around at least a portion of the sensor in vivo.

3. The device of claim 1 , wherein the biointerface membrane comprises a shape-memory material configured to be applied to the sensor in a first configuration, wherein after insertion into the tissue of the host the shape-memory material is configured to transform to a second configuration.

4. The device of claim 1 , wherein the biointerface membrane comprises an irritating architecture configured to promote fluid bulk surrounding at least a portion of the sensor in vivo by promoting an irritation and/or inflammation surrounding the sensor in vivo, thereby discouraging cells from stabilizing and building up an ordered, fibrous capsule during the time period.

Assignees

• Brauker James H
• Boock Robert
• Rixman Monica
• Simpson Peter C
• Brister Mark
• Shults Mark
• Dexcom Inc

Inventors

• Brauker James H
• Boock Robert
• Rixman Monica
• Simpson Peter C
• Brister Mark
• Shults Mark

Classifications

• A61B5/1473

  invasive, e.g. introduced into the body by a catheter · CPC title

• A61B5/6848

  Needles · CPC title

• G01N33/66

  involving blood sugars, e.g. galactose · CPC title

• G01N33/54366

  Apparatus specially adapted for solid-phase testing · CPC title

• A61B5/418

  lymph vessels, ducts or nodes · CPC title